Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018278 · ClinicalTrials.gov registry record · Phase 4
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
A Phase 4 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00018278: Completed Phase 4 study, sponsored by US Department of Veterans Affairs.
NCT00018278 is a Phase 4 study that has completed, run by US Department of Veterans Affairs. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018278, a Phase 4 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
Interventions
- DRUG Aricept
- DRUG Exelon
- DRUG Nicoderm Patch
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-10 |
| Est. Completion | 2001-09 |
| Phase | Phase 4 |
What the finished NCT00018278 record still lists
NCT00018278 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Aricept is the first listed.
NCT00018278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00018278 about?
NCT00018278 is a clinical study titled "Electrophysiologic Measures of Treatment Response in Alzheimer Disease". The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
What is the current status of trial NCT00018278?
This trial is currently completed. It is a Phase 4 study. The study started on 1998-10. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00018278?
The interventions under investigation include: Aricept (DRUG), Exelon (DRUG), Nicoderm Patch (DRUG).
Who is sponsoring clinical trial NCT00018278?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia